Status: Recruiting
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Participants needed: 64
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Cairo UniversityUpdated: May 16, 2025Locations: 1
Eligibility criteria
Age 18 and 65 years. [+2]
Patients with medication over use headache. [+3]